Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Children's Oncology Group

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Down Syndrome
Myelodysplastic Syndrome
Myeloid Leukemia Associated With Down Syndrome
Myeloproliferative Neoplasm

Interventions: Drug: Cytarabine
Drug: Asparaginase
Drug: Asparaginase Erwinia chrysanthemi
Drug: Daunorubicin Hydrochloride
Drug: Etoposide
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Drug: Thioguanine

First Posted Date: 2015-08-13

Last Posted Date: 2025-06-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 280

Registration Number: NCT02521493

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸
Banner Children's at Desert, Mesa, Arizona, United States

and more 188 locations

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Phase 2

Completed

Conditions: Refractory Osteosarcoma
Metastatic Osteosarcoma
Recurrent Osteosarcoma
Stage IV Osteosarcoma AJCC v7
Stage IVA Osteosarcoma AJCC v7
Stage IVB Osteosarcoma AJCC v7

Interventions: Biological: Denosumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-06-12

Last Posted Date: 2024-01-22

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 56

Registration Number: NCT02470091

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States

and more 138 locations

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Phase 2

Completed

Conditions: Recurrent Rhabdomyosarcoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Recurrent Neuroblastoma
Recurrent Synovial Sarcoma
Pleuropulmonary Blastoma
Wilms Tumor

Interventions: Other: Laboratory Biomarker Analysis
Biological: Lorvotuzumab Mertansine
Other: Pharmacological Study

First Posted Date: 2015-05-22

Last Posted Date: 2022-01-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 62

Registration Number: NCT02452554

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Kaiser Permanente Downey Medical Center, Downey, California, United States

and more 66 locations

MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Excluding CNS
Neuroblastoma

Interventions: Drug: MLN8237

First Posted Date: 2015-05-15

Last Posted Date: 2016-02-09

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 54

Registration Number: NCT02444884

Project: Every Child for Younger Patients With Cancer

Recruiting

Conditions: Congenital Mesoblastic Nephroma
Lymphoproliferative Disorder
Melanocytic Neoplasm
Neoplasm of Uncertain Malignant Potential
Neuroendocrine Neoplasm
Ganglioneuroma
Malignant Solid Neoplasm
Myeloproliferative Neoplasm
Childhood Langerhans Cell Histiocytosis
Childhood Mature Teratoma

Interventions: Other: Cytology Specimen Collection Procedure
Other: Medical Chart Review

First Posted Date: 2015-03-30

Last Posted Date: 2025-03-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 33000

Registration Number: NCT02402244

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 239 locations

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

Phase 3

Active, not recruiting

Conditions: Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

Interventions: Drug: Arsenic Trioxide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Drug: Tretinoin

First Posted Date: 2015-01-15

Last Posted Date: 2024-11-07

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 158

Registration Number: NCT02339740

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸
NYU Langone Hospital - Long Island, Mineola, New York, United States

and more 171 locations

Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Phase 1

Completed

Conditions: Recurrent Brain Neoplasm
Refractory Primary Central Nervous System Neoplasm
Recurrent Lymphoma
Refractory Lymphoma
Malignant Glioma
Recurrent Malignant Solid Neoplasm
Recurrent Childhood Central Nervous System Neoplasm
Recurrent Childhood Glioblastoma
Refractory Malignant Solid Neoplasm
WHO Grade 3 Glioma

Interventions: Other: Pharmacological Study
Drug: Selinexor

First Posted Date: 2014-12-24

Last Posted Date: 2025-01-14

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 59

Registration Number: NCT02323880

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 20 locations

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Neuroblastoma
Localized Unresectable Neuroblastoma

Interventions: Other: Clinical Observation
Procedure: Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Bone Marrow Biopsy
Procedure: Ultrasound
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide

First Posted Date: 2014-06-27

Last Posted Date: 2025-03-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 621

Registration Number: NCT02176967

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 219 locations

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Refractory or Recurrent Solid Tumors, Excluding CNS Tumors

Interventions: Drug: Axitinib

First Posted Date: 2014-06-17

Last Posted Date: 2018-01-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 51

Registration Number: NCT02164838

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital of Orange County, Orange, California, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States

and more 18 locations

Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma

Phase 1

Completed

Conditions: Unilateral Retinoblastoma

Interventions: Drug: Melphalan

First Posted Date: 2014-03-26

Last Posted Date: 2023-10-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 14

Registration Number: NCT02097134

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy